In 2018, major developments have been achieved in the diagnostic and therapeutic fields of CAR-T cell immunotherapy, next-generation sequencing (NGS), and targeted therapies. Several studies have demonstrated the benefits of CAR-T cells in refractory or relapsing diffuse large B-cell lymphomas. NGS is a major breakthrough in the diagnosis and management of patients with myeloid neoplasia and represents an important prognostic tool that will probably replace many other conventional factors in the future. Finally, several targeted therapies reviewed in this article are about to revolutionize the management of acute myeloblastic leukemia.
Relapsing diffuse B-cell lymphoma, immunotherapy, CAR-T cells, next-generation sequencing, targeted therapies, acute myeloblastic leukemia